Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

How immune-based interventions can change HIV therapy

Nature Medicine volume 3, pages 483–486 (1997)Cite this article

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kelleher, A.D., Can, A., Zaunders, J. & Cooper, D.A. Alterations in the immune response of human immunodeficiency virus (Hlv)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J. Infect. Dis. 173, 321–329 (1996).

    Article  CAS  Google Scholar 

  2. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582–1586 (1996).

    Article  CAS  Google Scholar 

  3. Fauci, A.S. Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 262, 1011–1018(1993).

    Article  CAS  Google Scholar 

  4. Corey, L.W. Reducing T cell activation as a therapy for human immunodeficiency virus infection. J. Infect. Dis. 171, 521–522 (1995).

    Article  CAS  Google Scholar 

  5. Emery, S. & Lane, H.C. Immune-based therapies in HIV infection: Recent developments. AIDS 10 (Suppl. A), S159–S163 (1996).

    Article  Google Scholar 

  6. Kovacs, J.A. et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335, 1350–1356 (1996).

    Article  CAS  Google Scholar 

  7. Clerici, M. et al. Restoration of HIV-specific cell-mediated immune response by in-terleukin-12 in vitro. Science 262, 1721–1724 (1996).

    Article  Google Scholar 

  8. Eberl, G. et al. Immunodominance of cytotoxic T lymphocyte epitopes co-injected in vivoand modulation by interleukin-12. Eur. J. Immunol. 26, 2709–2716.

  9. Pantaleo, G. & Fauci, A.S. Immunopathogenesis of HIV infection. Annu. Rev. Microbiol. 50, 825–854.

    Article  CAS  Google Scholar 

  10. Cocchi, F. et al. Identification of RANTES, MIP-1α and MIP-1β as the major HIV-suppressive factors produced by CDS+ T cells. Science 270, 1811–1815 (1995).

    Article  CAS  Google Scholar 

  11. Fauci, A.S. Host factors and the pathogenesis of HIV-induced disease. Nature 384, 529–533 (1996).

    Article  CAS  Google Scholar 

  12. Trinchieri, G. Resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13, 251–276 (1996).

    Article  Google Scholar 

  13. Pantaleo, G. et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355–359 (1993).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of AIDS Immunopathogenesis, Department of Medicine, Division of Infectious Diseases, Centre Hospitalier Universitaire Vadois, 1011, Lausanne, Switzerland

    Giuseppe Pantaleo

Authors
  1. Giuseppe Pantaleo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pantaleo, G. How immune-based interventions can change HIV therapy. Nat Med 3, 483–486 (1997). https://doi.org/10.1038/nm0597-483

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0597-483

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing